2025
Top advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approach
2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer
Morgensztern D, Ready N, Johnson M, Dowlati A, Choudhury N, Carbone D, Schaefer E, Arnold S, Puri S, Piotrowska Z, Hegde A, Chiang A, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson R, Hingorani P, Jeng E, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer. Clinical Cancer Research 2024, 30: 5042-5052. PMID: 39287821, PMCID: PMC11565168, DOI: 10.1158/1078-0432.ccr-24-1547.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleHumansImmunoconjugatesLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedSmall Cell Lung CarcinomaConceptsSmall cell lung cancerRelapsed/refractory small cell lung cancerTreatment-emergent adverse eventsCell lung cancerAdverse eventsLung cancerVeno-occlusive liver diseaseAntitumor activityResponse rateMedian response durationProgression-free survivalMaximum tolerated doseDose-expansion cohortPhase I studyIncreased aspartate aminotransferaseAntibody-drug conjugatesWeeks' monotherapyDose escalationPrior therapyTolerated doseMedian ageResponse durationLiver diseaseMonotherapyPatientsTargeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, Tani T, Nakayama J, Ma X, Thai T, Hung Y, Kim W, Watanabe H, Cai K, Hata A, Paweletz C, Barbie D, Cañadas I. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer. Cancer Research Communications 2024, 4: 2399-2414. PMID: 39177280, PMCID: PMC11391691, DOI: 10.1158/2767-9764.crc-24-0360.Peer-Reviewed Original ResearchConceptsSmall-cell lung cancerPatient-derived xenograftsCells to chemotherapyLung cancerInnate immune responseImmune responseSmall cell lung cancerHuman SCLC tumorsSurvival of resistant cellsResponse to chemotherapyCell lung cancerEfficacy of chemotherapyRepair exonuclease 1Postchemotherapy samplesAntitumor immunitySCLC tumorsCold tumorsAvailable therapiesChromatin immunoprecipitation sequencingTransposase-accessible chromatinInduce immunogenicityChemotherapyResistant cellsTherapeutic strategiesTREX1 expressionDetecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling
Zarif T, Meador C, Qiu X, Seo J, Davidsohn M, Savignano H, Lakshminarayanan G, McClure H, Canniff J, Fortunato B, Li R, Banwait M, Semaan K, Eid M, Long H, Hung Y, Mahadevan N, Barbie D, Oser M, Piotrowska Z, Choueiri T, Baca S, Hata A, Freedman M, Berchuck J. Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling. Clinical Cancer Research 2024, 30: 3798-3811. PMID: 38912901, PMCID: PMC11369616, DOI: 10.1158/1078-0432.ccr-24-0466.Peer-Reviewed Original ResearchConceptsEGFR mutant lung adenocarcinomaSmall cell lung cancerSmall cell transformationLung cancer patient-derived xenograftPatient-derived xenograftsLung adenocarcinomaEGFR mutantsChIP-seqEpigenomic featuresMeDIP-seqImmunoprecipitation sequencingCell transformationHistological transformation to small cell lung cancerTransformation to small cell lung cancerMethylated DNA immunoprecipitation sequencingTransposase-accessible chromatin sequencingH3K27ac ChIP-seqMechanisms of treatment resistanceChromatin immunoprecipitation sequencingHistone modification H3K27acMutant lung adenocarcinomaCell lung cancerChromatin accessibilityChromatin sequencingEpigenomic landscapePROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis
Shi M, Ding X, Tang L, Cao W, Su B, Zhang J. PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis. BMC Cancer 2024, 24: 504. PMID: 38644473, PMCID: PMC11034131, DOI: 10.1186/s12885-024-12244-3.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerMouse modelLung cancerRefractory small cell lung cancerNude miceIn vivo drug testingCell linesDrug testingLM cellsSensitivity of cisplatinIn vitro drug testingIncreased in vitroBackgroundLeptomeningeal metastasisLeptomeningeal metastasesSevere neurological disordersAssociated with several neurological disordersDrug sensitivityIn vivo live imagingHistological examinationCarotid arteryEffective treatmentMetastasisDrug trialsExpressing luciferaseTransformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
Ding X, Shi M, Liu D, Cao J, Zhang K, Zhang R, Zhang L, Ai K, Su B, Zhang J. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. Cell Communication And Signaling 2024, 22: 45. PMID: 38233864, PMCID: PMC10795321, DOI: 10.1186/s12964-023-01260-8.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSmall cell lung cancerSmall cell lung cancer transformationCell lung cancerTransformation to small cell lung cancerLung cancerEGFR-mutant non-small cell lung cancerMYC inhibitorsNon-small cell lung cancer patientsMechanisms of TKI resistanceEGFR mutation statusResistant lung cancerNon-small cell lung cancer cellsDriver gene statusPhenotype in vitroCancer-related genesPotential functional genesPutative gene functionsCRISPR-Cas 9SCLC transformationTKI resistanceMutation statusNeuroendocrine phenotypeRB1 statusClinical characteristicsTargeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer
Murayama T, Nakayama J, Jiang X, Miyata K, Morris A, Cai K, Prasad R, Ma X, Efimov A, Belani N, Gerstein E, Tan Y, Zhou Y, Kim W, Maruyama R, Campbell K, Chen L, Yang Y, Balachandran S, Canadas I. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer. Cancer Discovery 2024, 14: 468-491. PMID: 38189443, PMCID: PMC10905673, DOI: 10.1158/2159-8290.cd-23-0486.Peer-Reviewed Original ResearchMeSH KeywordsDEAD-box RNA HelicasesHumansImmunity, InnateInterferonsLung NeoplasmsNeoplasm ProteinsNucleic AcidsRNA, Double-StrandedSmall Cell Lung CarcinomaTumor MicroenvironmentConceptsSmall cell lung cancerDExD/H-box helicase 9Cell lung cancerCold tumorsLung cancerResponse to immune-checkpoint blockadeInnate immunityEnhance immunotherapy efficacyImmune-checkpoint blockadeImmunogenic tumor microenvironmentImmunologically cold tumorsNucleic acid-sensing pathwaysActivate innate immunityAntitumor immunityImmunotherapy efficacyReplication stressTumor microenvironmentTumor growthViral mimicryTumorImmune responseCancer cellsInterferon responseCytoplasmic dsRNACancer
2023
A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer
Ren Y, Zhang Z, She Y, He Y, Li D, Shi Y, He C, Yang Y, Zhang W, Chen C. A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer. Small Methods 2023, 8: e2300747. PMID: 37990399, DOI: 10.1002/smtd.202300747.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCase-Control StudiesCell-Free Nucleic AcidsEarly Detection of CancerHumansLung NeoplasmsSmall Cell Lung CarcinomaConceptsNon-small-cell lung cancerArea under the curveCell-free DNACell lung cancerBlood-based testLung cancerNon-small cell lung cancerLow-dose computed tomography screeningSmall cell lung cancerComputed tomography screeningCell-free DNA samplesEarly detection of lung cancerNon-invasive testsDetect cell-free DNADetection of lung cancerDetect lung cancerPulmonary nodulesSerum biomarkersDiagnostic accuracyHealthy controlsCancerTissue originLungEarly detectionPatientsUnderstanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoplasm Recurrence, LocalQuality of LifeSmall Cell Lung CarcinomaConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionalsAtezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Monjazeb A, Daly M, Luxardi G, Maverakis E, Merleev A, Marusina A, Borowsky A, Mirhadi A, Shiao S, Beckett L, Chen S, Eastham D, Li T, Vick L, McGee H, Lara F, Garcia L, Morris L, Canter R, Riess J, Schalper K, Murphy W, Kelly K. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nature Communications 2023, 14: 5332. PMID: 37658083, PMCID: PMC10474145, DOI: 10.1038/s41467-023-40813-w.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsRadiosurgerySmall Cell Lung CarcinomaConceptsNon-small cell lung cancerStereotactic ablative radiotherapyEarly-stage non-small cell lung cancerCell lung cancerAblative radiotherapyLung cancerMulti-institutional phase I trialSingle-arm phase IThird of patientsPhase I trialEx vivo stimulationT cell activationInoperable patientsPrimary endpointSecondary endpointsEfficacy signalsI trialT cellsAdaptive immunityCell activationPatientsPhase IPhase IIIEarly responseAtezolizumabNeuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
Biswas S, Kang K, Ng K, Radivoyevitch T, Schalper K, Zhang H, Lindner D, Thomas A, MacPherson D, Gastman B, Schrump D, Wong K, Velcheti V, Saunthararajah Y. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy. Cell Reports 2023, 42: 113016. PMID: 37597186, PMCID: PMC10528072, DOI: 10.1016/j.celrep.2023.113016.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell CycleCell DivisionLung NeoplasmsMiceSmall Cell Lung CarcinomaTumor Suppressor Protein p53ConceptsSmall cell lung cancerNon-cytotoxic therapiesImmune checkpoint inhibitorsCell lung cancerDNA methyltransferase 1SCLC cellsCytotoxic chemotherapyLung cancerDisseminated small cell lung cancerRepression marksSurvival of miceLineage commitmentCheckpoint inhibitorsResistant therapiesMaster transcription factorMaturation arrestTherapyTranscription factorsClinical compoundsMethyltransferase 1DNMT1 knockdownChemotherapyLineage maturationTranslocation 2Neuroendocrine lineageExportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus W, Zaidi S, Zhan Y, Manoj P, Sridhar H, Shah N, Chow A, Bhanot U, Linkov I, Asher M, Yu H, Qiu J, de Stanchina E, Patel R, Morrissey C, Haffner M, Koche R, Sawyers C, Rudin C. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Science Translational Medicine 2023, 15: eadf7006. PMID: 37531417, PMCID: PMC10777207, DOI: 10.1126/scitranslmed.adf7006.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsDown-RegulationHumansLung NeoplasmsMaleProstatic NeoplasmsSmall Cell Lung CarcinomaSOXB1 Transcription FactorsConceptsPatient-derived xenograftsProstatic adenocarcinomaNE transformationXenograft modelExportin 1Associated with poor prognosisProstate adenocarcinoma cell lineInactivation of TP53Adenocarcinoma xenograft modelEctopic SOX2 expressionEGFR inhibitor osimertinibAdenocarcinoma cell lineNE phenotypeNeuroendocrine transformationSelinexor treatmentStandard cytotoxicsProstate cancerLineage plasticityPotential therapeutic targetNE featuresPoor prognosisProstateSOX2 expressionAdenocarcinomaLungTracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa T, Weiss J, Schroeder M, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black J, Martínez-Ruiz C, Bakir M, Pich O, Watkins T, Lim E, Huebner A, Moore D, Godin-Heymann N, L’Hernault A, Bye H, Odell A, Kalavakur P, Gomes F, Patel A, Manzano E, Hiley C, Carey N, Riley J, Cook D, Hodgson D, Stetson D, Barrett J, Kortlever R, Evan G, Hackshaw A, Daber R, Shaw J, Aerts H, Licon A, Stahl J, Jamal-Hanjani M, Birkbak N, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023, 616: 553-562. PMID: 37055640, PMCID: PMC7614605, DOI: 10.1038/s41586-023-05776-4.Peer-Reviewed Original ResearchConceptsCirculating tumor DNANon-small-cell lung cancerMetastatic disseminationClinical outcomesPlasma samplesEarly-stage non-small-cell lung cancerCirculating tumor DNA levelsCirculating tumor DNA detectionCytotoxic adjuvant therapyPreoperative ctDNA detectionResidual tumor cellsLongitudinal plasma samplesCancer cell fractionBiomarker of relapseProcess of metastatic disseminationAnalysis of plasma samplesClinical relapseDisease relapseAdjuvant therapyTumor DNAPreoperative plasmaRadiological surveillanceCtDNA detectionPatient cohortTumor cells
2022
YES1 Is a Druggable Oncogenic Target in SCLC
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. YES1 Is a Druggable Oncogenic Target in SCLC. Journal Of Thoracic Oncology 2022, 17: 1387-1403. PMID: 35988891, DOI: 10.1016/j.jtho.2022.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCarcinogenesisCell Line, TumorCell ProliferationHumansLung NeoplasmsMiceOncogenesProto-Oncogene Proteins c-yesSmall Cell Lung CarcinomaConceptsSubpopulation of patientsOncogenic targetsPatient-derived xenograftsMarked antitumor activityGain/amplificationPlasma-derived exosomesDistant metastasisIndependent predictorsTargetable oncogenesPoor prognosisAggressive subtypeClinical managementLung cancerPharmacologic blockadeTumor regressionMouse modelTumor growthPlasma exosomesMolecular subgroupsPharmacologic inhibitionMetastasisAntitumor activityFunctional experimentsOrganoid modelsClinical samplesPOU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC
Baine MK, Febres-Aldana CA, Chang JC, Jungbluth AA, Sethi S, Antonescu CR, Travis WD, Hsieh MS, Roh MS, Homer RJ, Ladanyi M, Egger JV, Lai WV, Rudin CM, Rekhtman N. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal Of Thoracic Oncology 2022, 17: 1109-1121. PMID: 35760287, PMCID: PMC9427708, DOI: 10.1016/j.jtho.2022.06.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Large CellCarcinoma, NeuroendocrineGenomicsHumansLung NeoplasmsOctamer Transcription FactorsRepressor ProteinsSmall Cell Lung CarcinomaConceptsNeuroendocrine markersDiagnostic utilityLarge cell neuroendocrine carcinomaDiagnosis of SCLCSquamous cell carcinomaCell neuroendocrine carcinomaLung cancer typesMajor lung cancer typesNeuroendocrine marker expressionLung carcinoma subtypesWarrants further studyDistinct genomic alterationsClinical characteristicsCell carcinomaNeuroendocrine carcinomaLung tumorsCarcinoma subtypesLarge cohortDiagnostic mimicsTP53 alterationsMYC amplificationRecent markersTherapeutic targetingTuft cellsChallenging subsetSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal For ImmunoTherapy Of Cancer 2022, 10: e003956. PMID: 35640927, PMCID: PMC9157337, DOI: 10.1136/jitc-2021-003956.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansImmunotherapyLung NeoplasmsMesotheliomaMesothelioma, MalignantQuality of LifeSmall Cell Lung CarcinomaConceptsNon-small cell lung cancerSmall cell lung cancerClinical practice guidelinesLung cancerQuality of lifePractice guidelinesTreatment of NSCLCImmune-related adverse eventsCancer clinical practice guidelinesLung cancer careImmune checkpoint inhibitorsUse of immunotherapyFirst-line therapySubset of patientsCell lung cancerCancer care providersImmunotherapy of cancerConsensus-based recommendationsAdjuvant settingAdvanced diseaseCheckpoint inhibitorsAdverse eventsDurable responsesThoracic malignanciesAutoimmune disordersGraded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
Sperduto PW, De B, Li J, Carpenter D, Kirkpatrick J, Milligan M, Shih HA, Kutuk T, Kotecha R, Higaki H, Otsuka M, Aoyama H, Bourgoin M, Roberge D, Dajani S, Sachdev S, Gainey J, Buatti JM, Breen W, Brown PD, Ni L, Braunstein S, Gallitto M, Wang TJC, Shanley R, Lou E, Shiao J, Gaspar LE, Tanabe S, Nakano T, An Y, Chiang V, Zeng L, Soliman H, Elhalawani H, Cagney D, Thomas E, Boggs DH, Ahluwalia MS, Mehta MP. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 60-74. PMID: 35331827, PMCID: PMC9378572, DOI: 10.1016/j.ijrobp.2022.03.020.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSmall cell lung cancerGraded Prognostic AssessmentBrain metastasesSignificant prognostic factorsPrognostic factorsDeath ligand 1Cell lung cancerLung cancerPD-L1Lung adenocarcinomaMedian survivalNSCLC adenocarcinomaPrognostic assessmentInitial reportMulti-institutional retrospective databaseProgrammed Death Ligand 1PD-L1 1Tumor molecular statusOverall median survivalPD-L1 expressionLigand 1Anaplastic lymphoma kinaseEpidermal growth factor receptorGrowth factor receptorHealth-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research 2022, 28: 2286-2296. PMID: 35012927, PMCID: PMC9359973, DOI: 10.1158/1078-0432.ccr-21-3530.Peer-Reviewed Original ResearchMeSH KeywordsAcrylamidesAdjuvants, ImmunologicAniline CompoundsCarcinoma, Non-Small-Cell LungErbB ReceptorsHumansLung NeoplasmsMutationQuality of LifeSmall Cell Lung CarcinomaConceptsNon-small cell lung cancerWeek 96Short Form-36 Health SurveyDisease-free survival benefitSF-36 score changesMental component summary scoresPrior adjuvant chemotherapyComponent summary scoresHealth-related qualityCell lung cancerADAURA trialOral osimertinibAdjuvant chemotherapyAdjuvant treatmentSurvival benefitLung cancerHealth SurveySummary scoresScore changeOverall populationPlaceboLife outcomesOsimertinibDiscontinuationPatients
2021
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Molecular Cancer Therapeutics 2021, 20: 1820-1835. PMID: 34253596, PMCID: PMC8722383, DOI: 10.1158/1535-7163.mct-21-0013.Peer-Reviewed Original ResearchConceptsProtein phosphatase 2APhosphatase 2ASerine/threonine phosphataseDNA damage responseRegulation of apoptosisSmall molecule inhibitorsGlycolytic ATP productionThreonine phosphataseTwo-dimensional cultureLB100ATP productionMolecule inhibitorsPP2AThree-dimensional spheroid modelEndothelial cell monolayersGlucose uptakeCell viabilitySCLC cellsTherapeutic targetApoptosisCell monolayersMass spectrometrySpheroid modelTumor spheroidsCellsConsidering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply